Personalized medicine: Lung Cancer leads the way

Parikh, PM; Puri, Tipu S.

doi:10.4103/0019-509x.117005

Cited by 16 publications

(29 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e,f). Notably, the overall frequency of both EGFR and TP53 mutations was significantly higher in our NSCLC patients compared with patients in the COSMIC database, which can largely be attributed to racial differences between the two cohorts .…”

Section: Resultsmentioning

confidence: 75%

“…The unique spectra of gene mutations that occur within each patient necessitate a personalized approach to treating NSCLC. However, a number of commonly shared mutations have also been identified, including TP53 and EGFR , with the latter gene showing a considerably higher prevalence among Asian lung cancer patients . However, very few studies have examined whether these gene alterations are associated with clinical prognosis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Next‐generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome

Zhang

et al. 2016

Clinical Genetics

View full text Add to dashboard Cite

Large-scale genomic characterization of non-small cell lung cancer (NSCLC) has revealed several putative oncogenic driver mutations that may constitute druggable therapeutic targets. However, there are little data to suggest that such gene alterations have clinical relevance. Over 12 consecutive months, tumor biopsy samples from 80 patients with stage IV NSCLC were analyzed for mutations in selected exons of 508 cancer-related genes using next-generation sequencing. From 85 specimens referred for genomic characterization, 80 (94%) specimens were successfully genotyped, and all had identifiable somatic alterations. Epidermal growth factor receptor (EGFR) and TP53 genes contained the highest frequency of observed mutations (65% and 40%, respectively) in the stage IV NSCLC cases. Notably, patients with EGFR mutations showed a significantly shorter survival time compared with patients expressing wild-type EGFR (p = 0.0053). Moreover, of the 32 patients harboring EGFR mutations, EGFR-L858R mutant patients showed a significantly shorter survival time compared with patients with other EGFR mutations (p = 0.036). In conclusion, tumors from stage IV NSCLC patients harbor characteristic gene alterations, of which EGFR L858R in particular appears to be a poor prognostic factor for overall survival.

show abstract

Section: Resultsmentioning

confidence: 75%

mentioning

confidence: 99%

Next‐generation sequencing of Chinese stage IV lung cancer patients reveals an association between EGFR mutation status and survival outcome

Zhang

et al. 2016

Clinical Genetics

View full text Add to dashboard Cite

show abstract

“…Furthermore, the current information explosion and ongoing development of several hundreds of targeted drugs have the potential of making this useful in more and more patients in the future. [11,12] B. Molecular testing can involve:…”

Section: Introductionmentioning

confidence: 99%

“…This is due to better techniques of diagnosis, availability of better health-care facilities, higher number of qualified oncologists as well as the use of modern drugs to treat patients. [1,[10][11][12][13] Molecular genetics and its application for ascertaining the risk of cancer, its early detection, its accurate diagnosis, in selecting the right treatment and dose as well as helping assess the status at follow-up or recurrence are very important additional tools in the fight against cancer. [10][11][12][13][14]…”

Section: Introductionmentioning

confidence: 99%

Oncology Gold Standard™ consensus statement on counseling patients for molecular testing and personalized cancer care

Parikh

Hingmire

Bhavesh

et al. 2017

Int J Mol Immuno Oncol.

View full text Add to dashboard Cite

<p>Advances in molecular oncology technology and their application to personalized cancer care have evolved very rapidly over the past 5 years. At the same time, there are a lot of conflicting and often misleading statements available on the world wide web. This results in confusion and misunderstanding among cancer patients and their well-wishers. We realized that there was an urgent need for developing a consensus document to address this unmet need. Oncology Gold Standard and Molecular Oncology Society, therefore, took up the challenge and formed an expert group that together prepared this consensus statement on counseling patients for molecular testing and personalized cancer care. This is intended to benefit patients, family and friends by improving their broad understanding and equip them to make an informed decision and take active participation in decision-making for their own cancer management - with respect to prevention, diagnosis, treatment, and follow-up of cancer.</p>

show abstract

“…[17,18] This was based on pharmacogenomic differences between Asian and Caucasian people. [19] So it is considered as standard of care to treat patients with adenocarcinoma of the lung having EGFR mutations with gefitinib in the first line setting. Most of us also know that EGFR testing by genetic mutation analysis is what is clinically relevant and evaluating expression by immunohistochemistry should no longer be relied upon.…”

mentioning

confidence: 99%